Avalo Therapeutics, INC 10-Q quarterly reports

Avalo Therapeutics, Inc. announced positive Phase 2 results for abdakibart and a significant equity raise, bolstering its financial position and advancing its lead drug candidate.

Avalo Therapeutics announced positive Phase 2 data for abdakibart in hidradenitis suppurativa and completed a significant follow-on offering, bolstering its financial position.

Avalo Therapeutics reported a net loss of $64.5 million for the nine months ended September 30, 2025, but expects existing cash to fund operations into 2028, driven by progress in its AVTX-009 Phase 2 trial.

Avalo Therapeutics reports increased R&D spend for its lead asset AVTX-009's Phase 2 trial, while extending its cash runway into 2028.

Avalo Therapeutics reports a net loss of $13.1 million for Q1 2025, focusing on the development of AVTX-009 and the progression of the LOTUS trial.

Avalo Therapeutics reports a net income of $0.2 million for the nine months ended September 30, 2024, driven by a significant warrant liability adjustment and a recent $58.1 million capital raise from warrant exercises.

Avalo Therapeutics reports a net loss of $22.8 million for the first half of 2024, but is well-funded after a $115.6 million private placement and anticipates cash runway into 2027.

Avalo Therapeutics files an amended 10-Q report to correct a typographical error in certifications, following a significant private placement and asset acquisition.

Avalo Therapeutics completed a merger to acquire AVTX-009 and closed a significant private placement, while reporting a substantial net loss for the first quarter of 2024.